4/A: BiomX Inc. CEO Jonathan Solomon Receives Stock Options and Restricted Stock Units
Ownership Disclosure
BiomX Inc. CEO Jonathan Solomon received 126,748 Restricted Stock Units and options to purchase 380,500 shares of common stock, according to a Form 4/A filing.
Summary
- Jonathan Solomon, CEO of BiomX Inc., received 126,748 Restricted Stock Units (RSUs) on April 14, 2025.
- These RSUs are immediately vested and convert into BiomX Inc. common stock on a one-for-one basis.
- Solomon also received options to purchase 380,500 shares of BiomX Inc. common stock at an exercise price of $0.538 on April 14, 2025.
- The options vest over four years, with 25% vesting on April 14, 2026, and the remainder vesting in 12 equal quarterly installments over three years.
- This Form 4/A is an amendment to correct an administrative error in the original filing, specifically regarding the reporting of derivative securities acquired.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard executive compensation disclosure. The grants could be seen as positive for incentivizing management, but there's no immediate impact on the company's financials.
Positives
- The grant of RSUs and stock options to the CEO could incentivize him to improve company performance.
- The vesting schedule of the options encourages long-term commitment from the CEO.
Industry Context
Stock options and RSU grants are common compensation practices for executives in publicly traded companies, particularly in the biotech industry, to align their interests with those of shareholders.
Comparison to Industry Standards
- Executive compensation packages, including stock options and RSUs, are standard practice in the biotechnology industry.
- Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize similar compensation structures to incentivize their executives.
- The vesting schedules and exercise prices are generally benchmarked against industry peers to ensure competitiveness and retention.
Stakeholder Impact
- Shareholders may view the equity grants as a way to align management's interests with the company's long-term success.
- Employees may see the grants as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 04/14/2025 | Date of transaction: Grant of RSUs and stock options to Jonathan Solomon. |
| 04/14/2026 | First vesting date for 25% of the stock options. |
| 04/18/2025 | Date of original filing. |
| 04/21/2025 | Date of amended filing (Form 4/A). |
| 04/14/2035 | Expiration date of the stock options. |
Keywords
Form 4, BiomX Inc., Jonathan Solomon, Restricted Stock Units, Stock Options, Beneficial Ownership, PHGE, CEO, Vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.